Navigation Links
Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug exclusivities of key brands will impact the sustainability of this growth.

The new Spectrum report entitled Strategic Overview of Chronic and Acute Leukemias finds that 90 percent of patients respond to receiving Gleevec, presenting it as an ideal model for companies developing targeted leukemia therapies. However, while CML and CLL therapies are predicted to drive the leukemia market, the treatable-pool of chronic and acute leukemia patient populations -- CML, CLL, acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) -- is projected to grow at only low single-digit compound annual growth rates through 2015, which could potentially hamper research and development efforts.

"Patient population size could be considered a constraint to development of new drugs, since if patients are considered on the basis of genetic variants, the potential pool of treatable patients for a particular therapy can be further narrowed," states Matthew Drapeau, analyst with Decision Resources. "In addition, a lack of understanding of the etiology of leukemia is constraining clinical and commercial progress."

In addition to providing a forecast for key leukemia brands in the United States, France, Germany, Italy, Spain, and the United Kingdom, the Strategic Overview of Chronic and Acute Leukemias provides insight on:

  • U.S. hematological-oncologist opinions on diagnosis, current and emerging therapies, treatment decisions and other factors.
  • Leukemia treatment market drivers and constraints
  • Patent expiries and biosimilars competition

  • About Strategic Overview ReportsStrategic Overview reports are a new offering within the Spectrum franchise. These reports are comprehensive examinations of dynamic biopharmaceutical markets and industry issues. Primary research, data analysis, thought-leader consultation and the expertise of the industry-savvy Spectrum staff drive reports that offer breadth of coverage along with depth of strategic insight.

    About Decision ResourcesDecision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

    About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

    All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Erin O'Leary
    Decision Resources
    781-993-2641
    eoleary@dresources.com

    Elizabeth Marshall
    Decision Resources, Inc.
    781-993-2563
    emarshall@dresources.com
    '/>"/>

    SOURCE Decision Resources
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Sales Contracts Worth $2.3 Million Signed Since 1 July 2008
    2. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
    3. AMDL Inc. Announces Second Quarter 2008 Results; Company Posts $5.8 Million in Sales With a Revenue Increase of 140%
    4. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
    5. InVitria Expands Sales Team
    6. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
    7. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
    8. BioElectronics Corp Aggressively Expands Sales into Middle East
    9. Genstruct Names Louis Latino VP of Sales
    10. Guillermo Moreno Named Aurillions Vice President of Sales and Marketing
    11. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
    (Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named ... , Hunt Scanlon Media is one of the most respected life science publications ... human capital sector. , “It is a great honor for Slone Partners to be ...
    (Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch of ... on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit ... peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique set ...
    (Date:3/22/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... Chaim Lebovits , Chief Executive Officer, will provide ... at Sachs Associates 2 nd Annual Neuroscience Biopartnering ... at the New York Academy of Sciences. ...
    Breaking Biology Technology:
    (Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
    (Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
    (Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
    Breaking Biology News(10 mins):